

Thomas M. Jessell, et al.  
U.S. Serial No. : Not Yet Known  
(Continuation Application of  
PCT/US99/22517, filed 29 September 1999)  
Filed: Herewith  
Page 4

Claims 1-124 were pending in the subject application. By this Amendment applicants have canceled claims 2-5, 7-13, 15, 17, 19-20, 22-23, 25-26, 28-33, 35-37, 39-43, 46-47, 51, 53-55, 58-59, 62-65, 67-73, 75, 77, 79-80, 82-83, 85-86, 88-93, 95-97, 99-103, 106-107, 111, 113-115, and 118-119 without prejudice or disclaimer to applicants' right to pursue the subject matter of these claims in a future continuation or divisional application. Applicants have hereinabove amended claims 16, 34, 44-45, 48, 76, 94, 104-105, and 108. Applicants maintain that these amendments are made only to make the amended claims dependent on pending claims and do not raise any issue of new matter. Accordingly, upon entry of this Amendment, claims 1, 6, 14, 16, 18, 21, 24, 27, 34, 38, 44-45, 48-50, 52, 56-57, 60-61, 66, 74, 76, 78, 81, 84, 87, 94, 98, 104-105, 108-110, 112, 116-117, and 120-124 will be pending and under examination.

Pursuant to 37 C.F.R. §1.121(c)(1)(ii), applicants attach hereto as Exhibit A a version of the amended claims marked up to show the changes relative to the previous version thereof.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee other than the filing fee of \$913.00, is deemed necessary in connection with this Preliminary Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John R. White  
Registration No. 28,678  
Attorney for Applicant  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

100220 363236

Amended Claims:

16. (Amended) A method of producing a polypeptide having the biological activity of a mammalian MNR2 which comprises growing the host cells of claim[15] 14 under suitable conditions permitting production of the polypeptide.
34. (Amended) [A monoclonal] An antibody directed to an epitope of an MNR2 protein of claim [33]27.
44. (Amended) A method of producing the isolated protein of [either of] claim[s] 27 [or 28] which comprises:
- (a) inserting a nucleic acid molecule encoding a MNR2 protein into a suitable vector;
  - (b) introducing the resulting vector into a suitable host cell;
  - (c) selecting the introduced host cell for the expression of the MNR2 protein;
  - (d) culturing the selected cell to produce the MNR2 protein; and
  - (e) recovering the MNR2 protein produced.
45. (Amended) A method of inducing differentiation of somatic motorneurons in a subject comprising administering to the subject the purified MNR2 protein of [either of] claim[s] 27 [or 28] in an amount effective to induce differentiation of somatic motor neurons in the subject.
48. (Amended) A pharmaceutical composition comprising a purified MNR2 protein of [either of] claim[s] 27 [or 28] and a pharmaceutically acceptable carrier.
76. (Amended) A method of producing a polypeptide having the biological activity of a mammalian HB9 which comprises growing the host cells of claim [65] 74 under suitable conditions permitting production of the polypeptide.
94. (Amended) [A monoclonal] An antibody directed to an epitope of an HB9 protein of claim [93] 87.

